Matches in Wikidata for { <http://www.wikidata.org/entity/Q58297603> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q58297603 description "im Juli 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58297603 description "wetenschappelijk artikel" @default.
- Q58297603 description "наукова стаття, опублікована в липні 2018" @default.
- Q58297603 name "A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study" @default.
- Q58297603 name "A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study" @default.
- Q58297603 type Item @default.
- Q58297603 label "A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study" @default.
- Q58297603 label "A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study" @default.
- Q58297603 prefLabel "A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study" @default.
- Q58297603 prefLabel "A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study" @default.
- Q58297603 P1433 Q58297603-3CFA4B54-C560-4B53-8718-EC41E3BC23A4 @default.
- Q58297603 P1476 Q58297603-A230AA9A-60F2-42C0-9F31-E73087F60FA6 @default.
- Q58297603 P2093 Q58297603-0125684C-83C8-4C33-8FBE-CF66C71864EE @default.
- Q58297603 P2093 Q58297603-09A02353-4F97-407D-A90C-297A0AD4CE45 @default.
- Q58297603 P2093 Q58297603-1858B16C-9B3F-4CD0-AA28-D8C80BAAC0C5 @default.
- Q58297603 P2093 Q58297603-1EC75230-CAC1-459A-849B-7E7A587C0213 @default.
- Q58297603 P2093 Q58297603-278CC227-497A-4A46-ACC2-276E94952AC9 @default.
- Q58297603 P2093 Q58297603-5217CC4F-1691-4D5C-9E72-6E07E72BF211 @default.
- Q58297603 P2093 Q58297603-68B423B7-FCA4-49D5-97DF-0D382E49205C @default.
- Q58297603 P2093 Q58297603-7304890D-C533-40B1-99E4-0B5A78DE3BA5 @default.
- Q58297603 P2093 Q58297603-7CDFDACB-05EE-4D12-A114-CE19F407511F @default.
- Q58297603 P2093 Q58297603-8DA12CD8-9DE5-4DDC-94B0-AA72406A5779 @default.
- Q58297603 P2093 Q58297603-99D35E4F-32A0-4E17-9966-2568985397D0 @default.
- Q58297603 P2093 Q58297603-AE9F857A-8946-4022-8CC3-E47C1042BC6A @default.
- Q58297603 P2093 Q58297603-B9F8821A-033B-4466-9950-3186206F7B8F @default.
- Q58297603 P2093 Q58297603-BA606BB3-4A34-4A19-985E-DBF4015BE953 @default.
- Q58297603 P2093 Q58297603-D9032943-024B-4286-BB1B-4B27AF0CE290 @default.
- Q58297603 P2093 Q58297603-E98AEBE5-9F6C-4491-84C3-04399F73725B @default.
- Q58297603 P2093 Q58297603-F1742AE4-CA38-4C18-A357-6F969F8A5160 @default.
- Q58297603 P2093 Q58297603-F82C3CDC-13FC-4E46-952E-F9C3E4FBE432 @default.
- Q58297603 P2093 Q58297603-F959D194-046C-40FB-96FB-1FEE069E66B5 @default.
- Q58297603 P2093 Q58297603-FD3BCCCA-DDBA-4C4D-B444-2182AA6FF090 @default.
- Q58297603 P2093 Q58297603-FF5BB249-2EC5-4EC7-85F4-4DE992A68275 @default.
- Q58297603 P31 Q58297603-F14CC965-DA48-4380-90E3-B49BB1B069B9 @default.
- Q58297603 P356 Q58297603-DED4B41F-C283-45B8-9F63-B1A44891BF92 @default.
- Q58297603 P50 Q58297603-16957F7C-B993-401B-91D8-B0E996091F21 @default.
- Q58297603 P50 Q58297603-40CF9073-6ACE-4AFC-B517-77F01B96E40B @default.
- Q58297603 P577 Q58297603-4A5AF215-4507-445C-9057-AF529641B840 @default.
- Q58297603 P698 Q58297603-E1E3D55E-FC7E-4B0E-9C9E-32F3E29670DB @default.
- Q58297603 P921 Q58297603-14AC7A44-F9E7-4541-BF66-9355A552D4F2 @default.
- Q58297603 P921 Q58297603-A802D475-C326-438A-A3D3-18B7EAFBC72D @default.
- Q58297603 P356 J.DLD.2018.07.007 @default.
- Q58297603 P698 30077465 @default.
- Q58297603 P1433 Q15766194 @default.
- Q58297603 P1476 "A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study" @default.
- Q58297603 P2093 "Alex Johnston" @default.
- Q58297603 P2093 "Arash Assadsangabi" @default.
- Q58297603 P2093 "Belle Gregg" @default.
- Q58297603 P2093 "Ben Crooks" @default.
- Q58297603 P2093 "Catherine Kenneth" @default.
- Q58297603 P2093 "Catherine Stansfield" @default.
- Q58297603 P2093 "Chris Probert" @default.
- Q58297603 P2093 "Christian P. Selinger" @default.
- Q58297603 P2093 "Daniel Storey" @default.
- Q58297603 P2093 "Eleanor Liu" @default.
- Q58297603 P2093 "Elena Eliadou" @default.
- Q58297603 P2093 "Francesca Fairhurst" @default.
- Q58297603 P2093 "Jimmy K. Limdi" @default.
- Q58297603 P2093 "Karen Kemp" @default.
- Q58297603 P2093 "Paul Smith" @default.
- Q58297603 P2093 "Peter John Hamlin" @default.
- Q58297603 P2093 "Robert Willert" @default.
- Q58297603 P2093 "Salil Singh" @default.
- Q58297603 P2093 "Scott Levison" @default.
- Q58297603 P2093 "Sreedhar Subramanian" @default.
- Q58297603 P2093 "Suzanne Tattersall" @default.
- Q58297603 P31 Q13442814 @default.
- Q58297603 P356 "10.1016/J.DLD.2018.07.007" @default.
- Q58297603 P50 Q52812791 @default.
- Q58297603 P50 Q61310530 @default.
- Q58297603 P577 "2018-07-01T00:00:00Z" @default.
- Q58297603 P698 "30077465" @default.
- Q58297603 P921 Q120569 @default.
- Q58297603 P921 Q917447 @default.